[0:06:40] BB: You did tell me though, before we got on here, that you have some [emails] pulled that you wanted to share. Was that my understanding? 

[0:06:46] LL: Yeah. 

[0:06:47] BB: Do tell. I love when people have their homework ready. 

[0:06:50] LL: Yeah. I have some that I've starred that I've actually found to be very helpful pitches. 

[0:06:59] BB: That we love. Yes. 

[0:07:00] LL: Yeah. One is, animal law expert on federal and Trump administration response to bird flu outbreak. 

[0:07:07] BB: Oh, okay. What do you like about it? I'm like, “Oh, I already know some good juicy pieces.” But go ahead, go ahead, tell me. 

[0:07:12] LL: Yeah. I mean, I just, it tells me immediately what is in that email and it's not like I'm writing a story on this right now. However, I'm sure bird flu and whatever the Trump administration's policies are going to be around bird flu is something that's very much in my radar. I started this email immediately, because I was like, okay, this is something, someone I can go to if I need an expert source in that area. It was just very clear and, and easy to read. 

[0:07:44] BB: Okay. Boom. Right there in the subject line. Okay. Good job, publicists. What else do you have? 

[0:07:49] LL: I mean, another one is kind of similar vein future of drug regulation from Columbia University bioethicist POV. Same thing. This just – okay, here's a person that I can go to if I am doing some forward-looking trend story on what's going to happen with the FDA. I thought that was very useful. Then I would say that something I found – I also get a lot of pitches that are a little bit more wonky in the subject line – sorry, there was quite a few sirens – right now. Something is going down in DC. 

I get a lot of emails about data drops from companies. This one was embargoed SABCS data from Agenda/genomic tests. That's a harder subject line for me, because I'm not familiar with the company. I don't really know. There is so many acronyms in this world and I don't know what that – but I think obviously I know a lot as a reporter, but I can't remember every company. I think sometimes I get pitches where I'm like, this just doesn't – I don't know why this is important and why I should write about this. It's hard to add into a subject line for sure. But yeah, those are the ones that are a bit more challenging. 

[0:09:14] BB: Got you. Now, you said you don't read most of them. So, what do you do with the ones you don't read? Do you just trash them? Do you just never see them again? You just let it ride? 

[0:09:22] LL: I never trash. I feel, I'm too sentimental. I just – 

[0:09:28] BB: Me neither. Truly in mind. I'm just like, no, red. Okay. Great. Never see it again. 

[0:09:32] LL: Yeah. Exactly. I just mark as red, like it's good to have in there. I think it takes a lot for me to actually delete an email. I have to be like, all right, I just don't even want this. 

[0:09:43] BB: Good. Easy. 

[0:09:43] LL: To be around. Yeah. 

[0:09:45] BB: Yeah. Got you. Then what for you if any is a great pitch you want, let's say right now. You want to hear about X. 

[0:09:55] LL: I would say broadly, like the ones that I shared. I like pitches for expert sources, and especially like regulatory lawyers, like I can never – it's always useful to get that, even if I don't need it at that moment in time. I've often gone back and saved those emails for later. For right now, I mean, we're getting to the end of the year. I have a few stories I'm wrapping up that I have enough sourcing for, but I'm sure I've started to get these pitches and I don't want to get an influx of them, but it is helpful to get the – I'm going to be doing a what to care about as far as FDA next year or what are going to be the top items, like many publications having this kind of forward wrap up, forward looking story in each of our areas of coverage that's coming up. That'll be something I'm working on next week.